Want to join the conversation?
$AGN's products revenues jumped 112.8% to $3.51Bil. Botox revenue was $605MM for 3Q15 on continued strong performance in both aesthetic and therapeutic indications, and Restasis revenue was $328MM driven by continuing strong promotional efforts. Namenda XR revenue was $215MM as prescriptions and formulary coverage remained stable.
$NFLX a monster move, going up. Expect making some money on Monday.
$AMD down more than 6% even after posting above consensus third quarter results.
$MCD stock rose more than 2% after it posted better than expected 3Q16 results, driven by global same-store sales growth. Meanwhile, earnings and revenue were lower than last year, hurt by refranchising efforts.